Pharmaceutical company Cipla Ltd has said its wholly-owned subsidiary InvaGen Pharmaceuticals Inc’s manufacturing facility in New York has received a “No Action Indicated’ classification from the US health regulator.
A No Action Indicated (NAI) classification means no objectionable conditions or regulatory violations were found during an FDA facility inspection.
The United States Food and Drug Administration (USFDA) conducted the inspection of InvaGen Pharmaceuticals Inc’s manufacturing facility at Hauppauge, Long Island, New York, USA, from October 19 to October 22, 2026, the company said in a regulatory filing late on Tuesday evening.
The US health regulator issued the NAI classification to the company on November 17, 2026.
Published on November 18, 2026




